The potential of targeting Toll-like receptor 2 in autoimmune and inflammatory diseases

Eva M. Pålsson‐McDermott; Luke O'neill

doi:10.1007/s11845-007-0103-1

Related publications

Article2002

Toll-like receptors: new therapeutic targets for autoimmune diseases

Luke O'neill

Trends in Pharmacological Sciences

Article2005

Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease

Karl S. Lang, Mike Recher, Tobias Junt, Alexander A. Navarini, Nicola L. Harris, Stefan Freigang, Bernhard Odermatt, Curdin Conrad, Lars M. Ittner, Stefan Bauer, Sanjiv A. Luther, Satoshi Uematsu, Akira Shizuo, Hans Hengartner, Rolf M. Zinkernagel

Nature Medicine

Article2004

Toll-like receptor signalling

Akira Shizuo, Kiyoshi Takeda

Nature reviews. Immunology

Article2003

The Interleukin-1 Receptor/Toll-Like Receptor Superfamily

Aisling Dunne, Luke O'neill

Article2009

TANK is a negative regulator of Toll-like receptor signaling and is critical for the prevention of autoimmune nephritis

Tatsukata Kawagoe, Osamu Takeuchi, Yoshitsugu Takabatake, Hiroki Kato, Yoshitaka Isaka, Tohru Tsujimura, Akira Shizuo

Nature Immunology